DeepCure leverages AI and AI-enabled technologies to advance small molecule discovery techniques.
DeepCure has raised $24.6M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
DeepCure's investors include TLV Partners, E14 Fund, Creative Destruction Lab (CDL), IAG Capital Partners, Morningside.
DeepCure is headquartered in Boston, United States.
DeepCure leverages AI and AI-enabled technologies to advance small molecule discovery techniques.
DeepCure is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DeepCure — Funding & Investors." VCBacked, April 11, 2024, https://www.vcbacked.co/company/deepcure. Accessed July 19, 2026.
VCBacked. (2024). DeepCure — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/deepcure
{{cite web |title=DeepCure — Funding & Investors |url=https://www.vcbacked.co/company/deepcure |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated